U.S. markets open in 9 minutes
  • S&P Futures

    4,059.50
    -16.00 (-0.39%)
     
  • Dow Futures

    34,005.00
    -18.00 (-0.05%)
     
  • Nasdaq Futures

    12,038.25
    -68.50 (-0.57%)
     
  • Russell 2000 Futures

    1,902.90
    -7.60 (-0.40%)
     
  • Crude Oil

    82.30
    +1.29 (+1.59%)
     
  • Gold

    1,927.80
    -2.20 (-0.11%)
     
  • Silver

    23.60
    -0.42 (-1.75%)
     
  • EUR/USD

    1.0857
    -0.0035 (-0.33%)
     
  • 10-Yr Bond

    3.5290
    +0.0360 (+1.03%)
     
  • Vix

    18.79
    -0.29 (-1.52%)
     
  • GBP/USD

    1.2353
    -0.0054 (-0.43%)
     
  • USD/JPY

    129.8940
    -0.2590 (-0.20%)
     
  • BTC-USD

    22,921.36
    -260.87 (-1.13%)
     
  • CMC Crypto 200

    519.15
    -8.04 (-1.53%)
     
  • FTSE 100

    7,759.03
    -2.08 (-0.03%)
     
  • Nikkei 225

    27,382.56
    +19.81 (+0.07%)
     

Dynavax Adjuvant Based COVID-19 Vaccine Lowers The Risk Of Transmission

  • Clover Biopharmaceuticals Ltd announced that Clinical Infectious Diseases has published additional data from the SPECTRA Phase 2/3 trial that showed the SCB-2019 COVID-19 vaccine reduced the risk of transmission to household members compared to placebo participants.

  • Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus, and combined it with Dynavax Technologies Corp's (NASDAQ: DVAX) CpG 1018 advanced adjuvant and aluminum hydroxide (alum).

  • The study demonstrated that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household member had received SCB-2019 compared to households where the infected household member was not vaccinated.

  • Related: China-Based COVID-19 Shot Neutralizes Omicron Subvariants.

  • Among the 134 household contacts of infected household members who had received SCB-2019, there was one COVID-19 case; among the 250 household contacts of infected household members who were not vaccinated, there were 12 cases.

  • No cases of symptomatic SARS-CoV-2 infection among household contacts who were partially or fully vaccinated and where the infected household member was vaccinated with SCB-2019.

  • Clover is working towards completing regulatory submissions in China, Europe, and the World Health Organization for SCB-2019 by the end of 2022.

  • Price Action: DVAX shares closed at $11.88 on Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.